Exchange: NYSE·Updated 07:59 PM EDT

ABT News

News
all
press releases
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
Zacks
More News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks
Abbott declares 411th consecutive quarterly dividend
Abbott declares 411th consecutive quarterly dividend Abbott declares 411th consecutive quarterly dividendPR NewswireABBOTT PARK, Ill., Sept. 17, 2026 ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents...
PR Newswire
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.
Zacks
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recallPR NewswireABBOTT PARK, Ill., Sept. 14, 2026 Settlement does not represent any...
PR Newswire
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.
Zacks
Top Research Reports for Goldman Sachs, RTX & Abbott
Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.
Zacks
NVST or ABT: Which Is the Better Value Stock Right Now?
NVST vs. ABT: Which Stock Is the Better Value Option?
Zacks

Advertisement|Remove ads.